Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Given Consensus Rating of “Hold” by Analysts

Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) have been assigned an average recommendation of “Hold” from the fifteen research firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and six have issued a buy rating on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $32.71.

A number of research firms have weighed in on TNDM. Mizuho began coverage on shares of Tandem Diabetes Care in a research report on Thursday, April 10th. They set a “neutral” rating and a $20.00 target price for the company. Robert W. Baird reduced their price objective on shares of Tandem Diabetes Care from $33.00 to $24.00 and set a “neutral” rating for the company in a research report on Thursday, May 1st. Truist Financial started coverage on shares of Tandem Diabetes Care in a research report on Monday, June 16th. They set a “hold” rating and a $24.00 price objective for the company. Wells Fargo & Company reduced their price objective on shares of Tandem Diabetes Care from $22.00 to $20.00 and set an “equal weight” rating for the company in a research report on Thursday, May 1st. Finally, Stifel Nicolaus reduced their price objective on shares of Tandem Diabetes Care from $60.00 to $31.00 and set a “buy” rating for the company in a research report on Thursday, May 1st.

Tandem Diabetes Care Price Performance

Shares of TNDM opened at $14.77 on Friday. The company has a market cap of $983.83 million, a price-to-earnings ratio of -5.31 and a beta of 1.48. Tandem Diabetes Care has a 1-year low of $14.66 and a 1-year high of $47.60. The company’s fifty day simple moving average is $19.61 and its 200 day simple moving average is $23.66. The company has a current ratio of 2.30, a quick ratio of 1.81 and a debt-to-equity ratio of 1.99.

Tandem Diabetes Care (NASDAQ:TNDM) last issued its quarterly earnings data on Wednesday, April 30th. The medical device company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.07). Tandem Diabetes Care had a negative net margin of 18.71% and a negative return on equity of 57.33%. The company had revenue of $234.42 million during the quarter, compared to the consensus estimate of $220.19 million. During the same period in the previous year, the company earned ($0.65) earnings per share. Tandem Diabetes Care’s revenue for the quarter was up 22.3% compared to the same quarter last year. On average, research analysts forecast that Tandem Diabetes Care will post -1.68 earnings per share for the current fiscal year.

Institutional Trading of Tandem Diabetes Care

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. AlphaQuest LLC grew its holdings in shares of Tandem Diabetes Care by 138.7% during the 4th quarter. AlphaQuest LLC now owns 931 shares of the medical device company’s stock worth $34,000 after acquiring an additional 541 shares during the period. Assetmark Inc. grew its holdings in shares of Tandem Diabetes Care by 42.9% during the 1st quarter. Assetmark Inc. now owns 1,750 shares of the medical device company’s stock worth $34,000 after acquiring an additional 525 shares during the period. NBC Securities Inc. purchased a new position in shares of Tandem Diabetes Care during the 1st quarter worth approximately $37,000. Brooklyn Investment Group grew its holdings in shares of Tandem Diabetes Care by 417.8% during the 1st quarter. Brooklyn Investment Group now owns 3,397 shares of the medical device company’s stock worth $65,000 after acquiring an additional 2,741 shares during the period. Finally, State of Wyoming grew its holdings in shares of Tandem Diabetes Care by 49.1% during the 1st quarter. State of Wyoming now owns 4,467 shares of the medical device company’s stock worth $86,000 after acquiring an additional 1,471 shares during the period.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.